LU91273I2 - Natalizumab ou un de ses sels pharmaceutiquement acceptables (tysabri) - Google Patents

Natalizumab ou un de ses sels pharmaceutiquement acceptables (tysabri)

Info

Publication number
LU91273I2
LU91273I2 LU91273C LU91273C LU91273I2 LU 91273 I2 LU91273 I2 LU 91273I2 LU 91273 C LU91273 C LU 91273C LU 91273 C LU91273 C LU 91273C LU 91273 I2 LU91273 I2 LU 91273I2
Authority
LU
Luxembourg
Prior art keywords
present
receptor
beta
alpha
lymphocytes
Prior art date
Application number
LU91273C
Other languages
English (en)
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23591680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91273(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of LU91273I2 publication Critical patent/LU91273I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
LU91273C 1989-09-01 2006-08-10 Natalizumab ou un de ses sels pharmaceutiquement acceptables (tysabri) LU91273I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40238989A 1989-09-01 1989-09-01
PCT/US1990/004978 WO1991003252A1 (fr) 1989-09-01 1990-08-31 Inhibition de l'adhesion de lymphocytes sur l'endothelium vasculaire au moyen d'une nouvelle interaction entre le recepteur matriciel extra-cellulaire et son ligand

Publications (1)

Publication Number Publication Date
LU91273I2 true LU91273I2 (fr) 2006-10-10

Family

ID=23591680

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91273C LU91273I2 (fr) 1989-09-01 2006-08-10 Natalizumab ou un de ses sels pharmaceutiquement acceptables (tysabri)

Country Status (19)

Country Link
EP (2) EP0489837B2 (fr)
JP (1) JP3357359B2 (fr)
KR (1) KR100188459B1 (fr)
AT (1) ATE253642T1 (fr)
AU (1) AU654657B2 (fr)
CA (1) CA2065292C (fr)
DD (1) DD297562A5 (fr)
DE (3) DE122006000044I1 (fr)
DK (1) DK0489837T4 (fr)
ES (1) ES2210225T5 (fr)
FI (2) FI116793B (fr)
GR (2) GR1001161B (fr)
IE (2) IE20040028A1 (fr)
IL (3) IL113261A (fr)
LU (1) LU91273I2 (fr)
NL (1) NL300240I2 (fr)
NZ (1) NZ235131A (fr)
PT (1) PT95180A (fr)
WO (1) WO1991003252A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
WO1993012809A1 (fr) * 1991-12-24 1993-07-08 Fred Hutchinson Cancer Research Center Inhibition competitive du recepteur alpha4-beta1 a avidite elevee a l'aide du tripeptide ldv
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
DE69309044T3 (de) * 1992-01-13 2004-12-23 Biogen, Inc., Cambridge Behandlung von asthma
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
DK0682529T4 (da) † 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
EP0689609B2 (fr) † 1993-03-18 2005-04-13 N.V. Innogenetics S.A. Procede de typage de hla-b au moyen d'amorces specifiques et de groupes de sondes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
ES2424292T3 (es) * 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
FR2724393A1 (fr) * 1994-09-12 1996-03-15 Inst Nat Sante Rech Med Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
WO1997035557A1 (fr) * 1996-03-22 1997-10-02 Kao Corporation Composition topique pour soigner la peau
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
RU2359697C2 (ru) 2002-02-25 2009-06-27 Элан Фармасьютикалз, Инк. Введение средств для лечения воспаления
US7125650B2 (en) 2004-07-20 2006-10-24 Roberts David H Method for bump exposing relief image printing plates
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
WO1990008833A1 (fr) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression de la fibronectine de recombinaison dans des cellules mises au point par genie genetique

Also Published As

Publication number Publication date
NZ235131A (en) 1993-03-26
CA2065292C (fr) 2001-05-29
AU654657B2 (en) 1994-11-17
DE122006000044I1 (de) 2007-04-19
EP0489837A1 (fr) 1992-06-17
CA2065292A1 (fr) 1991-03-02
GR1001372B (el) 1993-10-29
NL300240I1 (nl) 2006-10-02
DE69034116D1 (de) 2003-12-11
GR1001161B (el) 1993-05-24
IL113261A (en) 1996-10-16
FI20050941A (fi) 2005-09-21
KR100188459B1 (ko) 1999-06-01
ES2210225T3 (es) 2004-07-01
NL300240I2 (nl) 2007-03-01
ATE253642T1 (de) 2003-11-15
DD297562A5 (de) 1992-01-16
ES2210225T5 (es) 2014-02-04
JP3357359B2 (ja) 2002-12-16
IE903169A1 (en) 1991-03-13
IL95501A (en) 1997-04-15
DE69034116T2 (de) 2004-08-26
EP0489837B2 (fr) 2013-11-13
AU6354290A (en) 1991-04-08
DE69034116T3 (de) 2014-06-18
DK0489837T3 (da) 2004-03-01
WO1991003252A1 (fr) 1991-03-21
IL113261A0 (en) 1995-07-31
GR900100648A (en) 1992-01-20
IE20040028A1 (en) 2004-05-05
PT95180A (pt) 1991-05-22
DE122006000044I2 (de) 2011-01-13
EP1366769A1 (fr) 2003-12-03
DK0489837T4 (da) 2013-11-18
FI116793B (fi) 2006-02-28
JPH05503070A (ja) 1993-05-27
EP0489837A4 (en) 1993-06-16
KR920703086A (ko) 1992-12-17
EP0489837B1 (fr) 2003-11-05
FI920899A0 (fi) 1992-02-28
FI118842B (fi) 2008-04-15

Similar Documents

Publication Publication Date Title
LU91273I2 (fr) Natalizumab ou un de ses sels pharmaceutiquement acceptables (tysabri)
Henocq et al. Skin eosinophilia in atopic patients
Limatibul et al. Theophylline modulation of E-rosette formation: an indicator of T-cell maturation.
Smith et al. Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes. Regulation of insulin-and cAMP-dependent activation by phosphorylation
Walsh et al. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner.
Gingerich Stratigraphic record of early Eocene Hyopsodus and the geometry of mammalian phylogeny
Simon et al. Mouse T-cell associated serine proteinase 1 degrades collagen type IV: a structural basis for the migration of lymphocytes through vascular basement membranes.
ATE330973T1 (de) Antagonisten von g protein-gekoppelten rezeptoren
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
DE69330372D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
CA2118309A1 (fr) Antigene hb15 d'activation lymphocytaire appartenant a la superfamille des immunoglobulines
Fabris et al. Fibrogenesis serum markers in patients with chronic hepatitis C treated with α-IFN
FI883351A0 (fi) Diagnostisk metod foer paovisande av stoerningar i rna-as l.
Lyberg Effect of cyclic AMP and cyclic GMP on thromboplastin (factor III) synthesis in human monocytes in vitro
LU81242A1 (fr) Composition en vue de reduire le taux de phenylalanine dans le sang,et son procede d'utilisation
Ballardini et al. Sequential behaviour of extracellular matrix glycoproteins in an experimental model of hepatic fibrosis
WO2002030256A3 (fr) Indicateur de diagnostic de la fonction thymique
WO1991008483A1 (fr) Il-8 a derivation endotheliale
Richard et al. Soybean trypsin inhibitor. An IL-1-like protein?
Sakagami et al. Differentiation-associated changes in human non-T, non-B leukemia cell lines after treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA)
CA2105606A1 (fr) Methode de detection des anticorps contre les agents anticoagulants du lupus qui causent la thrombose
Issekutz et al. Role of interleukin‐1 and tumour necrosis factor in leukocyte recruitment to acute dermal inflammation
DE790059T1 (de) Vorrichtung zur behandlung von auto-immunkrankheiten und verfahren zur behandlung
McArthur et al. 13. Modulation of lymphocyte functions by polymorphonuclear leukocyte-derived material.
KR900701834A (ko) 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법